摘要
目的探讨西格列汀及西格列汀与二甲双胍联合治疗2型糖尿病（T2DM）的临床疗效。方法将95例2型糖尿病患者随机分为西格列汀组（J组，30例）、二甲双胍组（M组，30例）、西格列汀和二甲双胍联合治疗组（U组，35例），J组服用西格列汀，M组服用二甲双胍，U组服用西格列汀与二甲双胍；治疗前、后检测患者空腹及餐后2小时血糖和胰岛素（FPG、2hPG、Fins、2hIns）、糖化血红蛋白（HbAlc），计算胰岛p细胞功能指数（HOMA—p）。结果3组患者血糖水平及HbA1c较治疗前降低（P均〈0．05），J组、U组患者HOMA—B较治疗前升高（P〈0．05）；治疗后，J组和U组患者HOMA—B高于M组（P均〈0．05），M组HbA1c及FPG水平均低于J组，但高于U组（P〈0．05），J组2hPG水平低于M组，但高于U组（P〈0．05）。结论西格列汀降糖疗效显著，与二甲双胍联合应用能进一步增强对2型糖尿病患者的治疗效果。
Objective To evaluate the clinical effect of sitagliptin and sitagliptin combined with metformin in the treatment of type 2 diabetes mellitus （ T2DM ）. Methods 95 patients with T2DM were randomly divided into sitagliptin group （group J）, metformin group （group M ） and sitagliptin combined with metformin group （group U）, group J took sitagliptin, group M took metformin, group U took sitagliptin and metformin. Before and after treatment, blood glucose and insulin were determined in the fasting and 2-hour blood samples after taking glucose （ FPG, 2hPG, Fins, 2hIns）, glycosylation hemoglobin （ HbA1 c） was also determined and homeostasis model assessment was applied to estimate the function index of islet 13-ce11（HOMA-13）. Results The levels of blood glucose and HbAlc in the three groups decreased after treatment （ P 〈 0.05 ）, HOMA-13 in group J and U increased after treatment （ P 〈 0.05 ）, HOMA-13 in group J and U was higher than that in group M（P 〈0.05） ,levels of HbAlc and FPG in group M were higher than those in group U but lower than those in group J（ P 〈 0.05 ） , level of 2hPG in group J was lower than that in group M but higher than that in group U （ P 〈 0.05 ）. Conclusion Sitagliptin provides significant glycaemic control, together with mefformin, clinical effect of treatment of type 2 diabetes will be enhanced.
出处
《临床内科杂志》
CAS
2012年第10期676-678,共3页
Journal of Clinical Internal Medicine
关键词
西格列汀
二甲双胍
2型糖尿病
Sitagliptin
Metformin
Type 2 diabetes mellitus
